July 16, 2025
Intangible Assets

How Regeneron is using patent tactics to try to thwart competition

A court battle between two of the nation’s largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal limits of how far drugmakers can go in using patents to thwart competition. And the case is being closely watched by companies that sell biosimilar medicines amid concerns that the U.S. patent system is being

Read More
Intangible Assets

Federal court reopens question of who owns key CRISPR patents

Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach Megan on Signal at mmolteni.13. The now 13-year-long legal saga over who invented CRISPR took yet another unexpected turn on Monday, in a ruling that

Read More
Intangible Assets

Pharmalittle: We’re reading about FDA scrambling for workers, Pfizer CEO pay and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to promenade with the official mascots, catch up on our reading and look in on the

Read More